

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on January 16, 2002, from 10 a.m. to 12:30 p.m.

Location: Holiday Inn, Versailles Ballrooms I and II, 8120 Wisconsin Ave., Bethesda, MD.

Contact: William Freas, or Sheila D. Langford, Center for Biologics Evaluation and Research (CBER) (HFM-17), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852-1448, 301-827-0314, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 19516. Please call the Information Line for up-to-date information on this meeting.

Agenda: On January 16, 2002, the committee will hear presentations relevant to the site visit report on the review of the research programs of the Laboratory of Bacterial, Parasitic, and Unconventional Agents, and the Laboratory of Molecular Virology, Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, CBER.

Procedure: On January 16, 2002, from 10:00 a.m. to 10:45 a.m., and from 11:30 a.m. to 12:30 p.m. the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by January 9, 2002. Oral presentations from the public will be scheduled between approximately 11:30 a.m. to 12:30 p.m. on January 16, 2002. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before January 9, 2002, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Closed Committee Deliberations: On January 16, 2002, from 10:45 a.m. to 11:30 a.m., the meeting will be closed to permit discussion where disclosure would constitute a clearly unwarranted invasion of personal privacy (5 U.S.C. 552b(c)(6)). The committee will discuss the reports of the review of individual research programs in the Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, Center for Biologics Evaluation and Research.

FDA regrets that it was unable to publish this notice 15 days prior to the

January 16, 2002, Blood Products Advisory Committee meeting. Because the agency believes there is some urgency to bring this issue to public discussion and qualified members of the Blood Products Advisory Committee were available at this time, the Commissioner of Food and Drugs concluded that it was in the public interest to hold this meeting even if there was not sufficient time for the customary 15-day public notice.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: December 26, 2001.

Linda A. Suydam,

Senior Associate Commissioner.

[FR Doc. 01-32253 Filed 12-27-01; 5:02 pm]

BILLING CODE 4160-02-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of Inspector General

Program Exclusions: November 2001

AGENCY: Office of Inspector General, HHS.

ACTION: Notice of program exclusions.

During the month of November 2001, the HHS Office of Inspector General imposed exclusions in the cases set forth below. When an exclusion is imposed, no program payment is made to anyone for any items or services (other than an emergency item or service not provided in a hospital emergency room) furnished, ordered or prescribed by an excluded party under the Medicare, Medicaid, and all Federal Health Care programs. In addition, no program payment is made to any business or facility, e.g., a hospital, that submits bills for payment for items or services provided by an excluded party. Program beneficiaries remain free to decide for themselves whether they will continue to use the services of an excluded party even though no program payments will be made for items and services provided by that excluded party. The exclusions have national effect and also apply to all Executive Branch procurement and non-procurement programs and activities.

Subject city, state	Effective date
Program-Related Convictions	
Bilenkin, Elana Old Bridge, NJ	12/20/2001
Birdsong, Stacie Detroit, MI	12/20/2001
Bitz, Jennifer M Jamestown, ND	12/20/2001

Subject city, state	Effective date
Boguslavskiy, Vadim Lavenel, NJ	12/20/2001
Brown, Maurice Chevale Sterling, CO	12/20/2001
Dallakyan, Naira M Pasadena, CA	12/20/2001
Greer, J Randall Memphis, TN	12/20/2001
Gutman, Marci Miami, FL	12/20/2001
Maddox, Yolanda Gail Troy, AL	12/20/2001
McDonald, Anita Fletcher Palestine, TX	12/20/2001
New York Health Plan New York, NY	12/20/2001
Norman, Brigid Riverdale, GA	12/20/2001
Paulin, John Gregory Florence, CO	12/20/2001
Rapp, Donna Lynn Lakewood, CO	12/20/2001
Reyes, Gloria Miami, FL	12/20/2001
Rose, Melba L Miami, FL	12/20/2001
Scarpitta, Janet Newark, NJ	12/20/2001
Stolyar, Yelena Golden, CO	12/20/2001
Taylor, Shirley Jean Pearl, MS	12/20/2001
Urban, Edward J Chargin Fall, OH	12/20/2001

Felony Conviction for Health Care

Brathwaite, Stephen Earl W Valley City, UT	12/20/2001
Burstein, Donald A Warminster, PA	12/20/2001
Casiano, Janet Carle Place, NY	12/20/2001
Fergusson, Olantungie Clar- ence Sherman Oaks, CA	12/20/2001
Oldham, Susan G Lexington, KY	12/20/2001
Runk, Lisa D Wichita, KS	12/20/2001
Seals, Carlos V Los Angeles, CA	12/20/2001

Felony Control Substance Conviction

Davis, Donna K Kidd Somerset, KY	12/20/2001
Gleason, Laura Jane Phoenix, AZ	12/20/2001
Hendrick, Vickie Gallatin, TN	12/20/2001
McMenamin, Deborah J Carbondale, PA	12/20/2001
Sommer, Deborah Jane Dayton, TX	12/20/2001

Patient Abuse/Neglect Convictions

Barsuk, Joseph Jr Churchville, NY	12/20/2001
Boykins, Loretta Penny Baltimore, MD	12/20/2001
Cathey, Deborah Baltimore, MD	12/20/2001

Subject city, state	Effective date	Subject city, state	Effective date	Subject city, state	Effective date
Nashville, TN		Leonard, Rhonda Lynn	12/20/2001	Pembroke Pines, FL	
Coleman, Tracy Lavonne	12/20/2001	Tyler, TX		Buckingham, Guy M	12/20/2001
Laurora, CO		Long, Jill Suzanne	12/20/2001	Orleans, MI	
Conyers, Leonard E	12/20/2001	W Blocton, AL		Dauphin, Michelle M	12/20/2001
Wilmington, DE		Lucero, Glen M	12/20/2001	Pembroke Pines, FL	
Dickinson, Sharon Lee	12/20/2001	Denver, CO		Dinozzi, Anthony D	12/20/2001
Corunna, MI		McGraw, Daniel P	12/20/2001	Batavia, OH	
Ferdon, Michael Kevin	12/20/2001	Haverhill, MA		Dupuis, Edward J	12/20/2001
Ontario, OR		Milam, Stephen Robert	12/20/2001	Dallas, TX	
Kegel, Alan	12/20/2001	Cicero, IN		Evans, Charla J	12/20/2001
Wheeling, IL		Moore, Jerry Gayle	12/20/2001	Mobile, AL	
Lembong, Noky Herems	12/20/2001	Houston, TX		Ferguson, Camilla M	12/20/2001
Diamond Bar, CA		Newman, William T	12/20/2001	Fairborn, OH	
Maxian, Therese M	12/20/2001	Chapel Hill, NC		Fredericks, Duane A	12/20/2001
Binghamton, NY		Petanovich, E John	12/20/2001	Philadelphia, PA	
Pawlak, Patricia	12/20/2001	Emlenton, PA		Fryer, Thomas J	12/20/2001
Barker, NY		Peyton, Bret W	12/20/2001	Ferron, UT	
Quinones, Anel	12/20/2001	Iowa Falls, IA		Gilyot, Glenn David Sr	12/20/2001
Garfield, NJ		Porter, Mary Jo	12/20/2001	New Orleans, LA	
Risley, Charles	12/20/2001	Norfolk, VA		Hansen, Hunter J	12/20/2001
S Saugerties, NY		Rice, Cynthia M	12/20/2001	Andrews, NC	
Stocker, Charles Edward	12/20/2001	Phoenix, AZ		Havriliak, Stephen J	12/20/2001
Lancaster, OH		Richardson, Lawrence John	12/20/2001	Huntingdon Valley, PA	
Thompson, Robert J	12/20/2001	Los Angeles, CA		Huber, Mark	12/20/2001
Raymond, MS		Rollins, Jane	12/20/2001	Princeton, MN	
Watson, Marlene Maria	12/20/2001	Michigan City, IN		Kardelis, Eugene C Jr	12/20/2001
Bronx, NY		Shellhase, Barbara J	12/20/2001	Nazareth, PA	
Conviction for Health Care Fraud		Cleona, PA		Kardos, William P	12/20/2001
Plyter, Mark	12/20/2001	Spencer, Craig A	12/20/2001	Apollo, PA	
Williamson, NY		Frankfort, IL		Knott, Kevin Thomas Jr	12/20/2001
License Revocation/Suspension/ Surrendered		Sugden, Mark F	12/20/2001	Oceanside, CA	
Amundson, Terri Sue	12/20/2001	Virginia Beach, VA		Kron, Kathy A	12/20/2001
Lawrenceville, GA		Tabotabo, Armando M	12/20/2001	Norton, MA	
Banda-Orman, Selina	12/20/2001	Keyport, NJ		Lallouz, Solomon Y	12/20/2001
Des Moines, IA		Vail, Sheree Behr	12/20/2001	Hollywood, FL	
Barolin, Linda	12/20/2001	Malvern, PA		Lantz, Larry S	12/20/2001
Mantua, NJ		Wehby, Michael Daniel	12/20/2001	Broomall, PA	
Bealer, Mildred Sith	12/20/2001	Fort Thomas, KY		Leavitt, Albert M Jr	12/20/2001
Pottsville, PA		West, Malynda Susan	12/20/2001	Alexandria, VA	
Bell, Donna S	12/20/2001	San Francisco, CA		Legault, Michelle A	12/20/2001
Douglas, AK		Fraud/Kickbacks		Coon Rapids, MN	
Bryant, Laurie L	12/20/2001	Rousseau, Andre M	09/10/2001	Leon, Maria I	12/20/2001
Davenport, IA		Chicago, IL		Hollywood, FL	
Burgess, Marleen K	12/20/2001	Entities Owned/Controlled By Convicted		Levy, Richard S	12/20/2001
Cresco, IA		Arroyo Chiropractic	12/20/2001	Forthee, NJ	
Carico, Paula J	12/20/2001	Arroyo Grande, CA		Milbourne, Michael W	12/20/2001
Kendallville, IN		Carlin Chiropractic Health Ctr ..	12/20/2001	Lafayette Hill, PA	
Cigelske, Michael Allen	12/20/2001	San Antonio, TX		Milot, Sheila Inez	12/20/2001
Phoenix, AZ		Cosmetic Surgery & Laser Inst	12/20/2001	Vernon Hills, IL	
Duffie, Brenda L	12/20/2001	Tustin, CA		Moore, Charles E	12/20/2001
Burlington, IA		Gregory W Stephens, D C, P C	12/20/2001	Kansas City, KS	
Dykes, Judy R	12/20/2001	Houston, TX		O'Brien, Matthew P	12/20/2001
Phoenix, AZ		Lund Chiropractic	12/20/2001	Romeo, MI	
Garrett, Herman Alpha	12/20/2001	Arlington, TX		Parenti, Lisa C	12/20/2001
Norcross, GA		Martin Family Chiropractic Ctr ..	12/20/2001	Nashville, TN	
Harple, Carol Weiler	12/20/2001	Cameron Park, CA		Parker, Melissa M	12/20/2001
Gordonville, PA		Y & L Corporation	12/20/2001	Clinton, NC	
Hernandez, Stephen Louis	12/20/2001	Denver, CO		Parsons, Tien M	12/20/2001
Hudson, FL		Default on Heal Loan		Marathon, FL	
Heuberger, Sally	12/20/2001	Alams, Humphrey A Jr	12/20/2001	Payne, Carrol D	12/20/2001
Sheffield, IA		Seattle, WA		Memphis, TN	
Hummell, Alan	12/20/2001	Anillo-Sarmiento, Manuel F	12/20/2001	Pitts, Angela R	12/20/2001
Cocoa, FL		Miami, FL		Odessa, FL	
Jewkes, Mindy	12/20/2001	Baron, Spencer H	12/20/2001	Powell, Michael N	12/20/2001
Salt Lake City, UT		Bell, Robert E	12/20/2001	Wollaston, MA	
Kadish, William A	12/20/2001	Phoenix, AZ		Pugh, Melvoria C	12/20/2001
Shrewsbury, MA		Bornstein, Mark L	12/20/2001	Mobile, AL	
Larson, Richard Warren	12/20/2001			Ray, Donald Elton	12/20/2001
Cherokee Village, AR				Orange Beach, AL	
				Richichi, Mark S	12/20/2001
				Ctr Moriches, NY	
				Roberts, Pamela	12/20/2001
				Charlotte, NC	

Subject city, state	Effective date
Robinson, Cynane Ann Yetta ... Southfield, MI	12/20/2001
Rodebaugh, Cheryl Lynn Denver, CO	12/20/2001
Rose, Keith D Big Rapids, MI	12/20/2001
Roudebush, Mark D Cordova, TN	12/20/2001
Rouselle, Dionne Marie Memphis, TN	12/20/2001
Rubinstein, David M Tamarac, FL	12/20/2001
Schwirian, Jay A White Oak, PA	12/20/2001
Smith, Terrance Herbert Sioux Falls, SD	12/20/2001
Smith, William H III Philadelphia, PA	12/20/2001
Sparks, Darlene V Annandale, VA	12/20/2001
Stevens, Joanne K Broadview Hgts, OH	12/20/2001
Strasser, Robert T Lake Zurich, IL	12/20/2001
Thompson, Emma R Lithonia, GA	12/20/2001
Van Brookhoven, Gloria Atlanta, GA	12/20/2001
Vodvarka, James M Steubenville, OH	12/20/2001
Webb, James R Shawnee Mission, KS	12/20/2001
Wohlschlaeger, Michael Alan ... Panama City Bch, FL	12/20/2001
Wolf, Jacob M Akron, OH	12/20/2001
Wright, Bill G Lincoln, NE	12/20/2001
Yoder, Patricia L Ocklawaha, FL	12/20/2001
Young-Cheney, Joan E Creswell, OR	12/20/2001

Peer Review Organization Cases

Hinkley, Bruce Stanton Dallas, TX	11/14/2001
--	------------

Dated: December 3, 2001.

Calvin Anderson, Jr.,*Director, Health Care Administrative
Sanctions, Office of Inspector General.*

[FR Doc. 01-32156 Filed 12-31-01; 8:45 am]

BILLING CODE 4150-04-P

**DEPARTMENT OF HEALTH AND
HUMAN SERVICES****National Institutes of Health****Government-Owned Inventions;
Availability for Licensing****AGENCY:** National Institutes of Health,
Public Health Service, DHHS.**ACTION:** Notice.**SUMMARY:** The inventions listed below
are owned by agencies of the U.S.
Government and are available for

licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by contacting Peter A. Soukas, J.D., at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7056 ext. 268; fax: 301/402-0220; e-mail: soukasp@od.nih.gov. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

LL-37 is an Immunostimulant

Oleg Chertov (NCI), Joost Oppenheim (NCI), De Yang (NCI), Qian Chen (NCI), Ji Wang (NCI), Mark Anderson (EM), Joseph Wooters (EM)
Serial No. 09/960,876 filed 21 Sep 2001

This invention relates to use of an antimicrobial peptide as a vaccine adjuvant. LL-37 is the cleaved antimicrobial 37-residue C-terminal peptide of hCAP18, the only identified member in humans of a family of proteins called cathelicidins. LL-37/hCAP18 is produced by neutrophils and various epithelial cells. LL-37 is well known as an antimicrobial peptide. However, although antimicrobial peptides have generally been considered to contribute to host innate antimicrobial defense, some of them may also contribute to adaptive immunity against microbial infection. The inventors have shown that LL-37 utilizes formyl peptide receptor-like 1 (FPLR1) as a receptor to activate human neutrophils, monocytes, and T cells. Since leukocytes participate in both innate and adaptive immunity, the fact that LL-37 can chemoattract human leukocytes may provide one additional mechanism by which LL-37 can contribute to host defense against microbial invasion, by participating in the recruitment of leukocytes to sites of infection. The invention claims methods of enhancing immune responses through the administration of LL-37 alone, in conjunction with a vaccine, and methods of treating autoimmune diseases. The invention is further described in Chertov et. al., "LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPLR1) as a receptor to chemoattract human

peripheral blood neutrophils, monocytes, and T cells," *J Exp. Med.* 2000 Oct 2;192(7):1069-74.

**A Method for Bioconjugation Using
Diels-Alder Cycloaddition**

Vince Pozsgay (NICHD)
Serial Number 09/919,637 filed 01 Aug 2001

This invention relates to a new method for the synthesis of conjugate vaccines using the Diels-Alder cycloaddition reaction to covalently attach a carbohydrate antigen from a pathogen to a protein carrier. The Diels-Alder reaction has not been extended to conjugation involving biopolymers or other types of polymeric materials. Advantages of this method are that cross-linking during conjugation is entirely avoided in addition to the mild chemical conditions under which this synthesis method proceeds. Diels-Alder reactions commonly take place in high-temperature environments; the method contemplated by this invention takes place at much lower temperatures. In addition to claiming methods of synthesis for conjugate vaccines using the Diels-Alder cycloaddition, the patent application claims vaccines produced utilizing the method, and methods of inducing antibodies which react with the polysaccharides contemplated by the invention.

**Identification of New Small RNAs and
ORFs**

Susan Gottesman (NCI), Gisela Storz (NICHD), Karen Wassarman (NICHD), Francis Repoila (NCI), Carsten Rosenow (EM)

Serial No. 60/266,402 filed 01 Feb 2001
The inventors have isolated a number of previously unknown sRNAs found in *E. coli*. Previous scientific publications by the inventors and others regarding sRNAs have shown these sRNAs to serve important regulatory roles in the cell, such as regulators of virulence and survival in host cells. Prediction of the presence of genes encoding sRNAs was accomplished by combining sequence information from highly conserved intergenic regions with information about the expected transcription of neighboring genes. Microarray analysis also was used to identify likely candidates. Northern blot analyses were then carried out to demonstrate the presence of the sRNAs. Three of the sRNAs claimed in the invention regulate (candidates 12 and 14, negatively and candidate 31, positively) expression of RpoS, a major transcription factor in bacteria that is important in many pathogens because it regulates (amongst other things) virulence. The inventors' data show that these sRNAs are highly